Allogene Therapeutics(US:ALLO) ZACKS·2025-09-12 16:31Company Overview - Allogene Therapeutics reported a narrower than expected loss of 23 cents per share for Q2 2025, compared to the Zacks Consensus Estimate of a loss of 28 cents and a loss of 35 cents per share in the same period last year [2] - The company did not report any sales during the quarter, as it lacks a marketed product, while it recorded collaboration revenues of $0.02 million in the year-ago period [2] Financial Performance - Research and development (R&D) expenses totaled $40.2 million, down 20.2% from the previous year [3] - General and administrative expenses decreased by 11.2% year over year to $14.3 million [3] - As of June 30, 2025, Allogene had $302.6 million in cash, cash equivalents, and investments, down from $335.5 million as of March 31, 2025 [3] Future Guidance - The company expects operating expenses for 2025 to be around $230 million and cash burn to be approximately $150 million, indicating that its cash runway will fund operations into the second half of 2027 [4] Market Sentiment - Since the earnings release, there has been an upward trend in estimates revision for Allogene Therapeutics [5] - The stock has a Zacks Rank 2 (Buy), indicating expectations for above-average returns in the coming months [7] Industry Comparison - Allogene Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Beam Therapeutics Inc. has gained 22.2% over the past month [8] - Beam Therapeutics reported revenues of $8.47 million for the last quarter, reflecting a year-over-year decline of 28% [9]